News | March 15, 2026
China’s NMPA approves Zydus-licensed anaemia drug Desidustat
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The protections extend through at least 2035, with the potential for further extensions
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
One task, one interaction, one pair, experts advocate
The endorsement follows overwhelming support for the share swap preceding the merger,
The conflict is also triggering a widening public health emergency
Subscribe To Our Newsletter & Stay Updated
